Treatment Details – 8.8 months
|Patients: This Phase II study involved 26 patients with malignant pleural mesothelioma. Twenty-one patients were men, and five were women. The median age was 60 years. None of the patients had received chemotherapy prior to treatment.|
Treatment: The treatment consisted of two chemotherapeutic agents: vinorelbine and oxaliplatin.
Toxicities: Grade 3-4 toxicities included: neutropenia, phlebitis, malaise, anorexia,
Results: The median survival was 8.8 months. The authors concluded “vinorelbine with oxaliplatin appears to be no more effective than vinorelbine monotherapy and is associated with more frequent symptomatic toxicity than single agent. It is, therefore, not recommended for the treatment of MPM.”
Correspondence: Dean A. Fennell, MD